External Controls: Sarepta’s DMD Gene Therapy Not In the Same Boat As Zolgensma, US FDA Says
Executive Summary
Sarepta conducted study-level and integrated-level comparison analyses of SRP-9001-treated patients and external controls. However, heterogeneous nature of DMD and potentially moderate treatment effect of SRP-9001 distinguish it from Novaritis' spinal muscular atrophy treatment, where natural history data were used to support single-arm trial results, the FDA said.
You may also be interested in...
Slim Adcomm Majority Boosts Sarepta’s Gene Therapy In Duchenne Muscular Dystrophy
Accelerated approval seems imminent after a majority of the US FDA’s Cellular, Tissue and Gene Therapies Advisory Committee voted the risk-benefit balance supported it.
External Controls: FDA Guidance Provides Clarity But Does Little To Remove Hurdles
Agency discourages use of externally controlled trials in all but a very limited number of situations truly ripe for such an approach; new draft guidance discusses at length the various confounding factors that can introduce bias into a comparison between an investigational treatment and an external control using either real-world data or data from another clinical trial.
Baby Steps To Real-World Evidence Of Efficacy: External Controls Gain Popularity In Rare Disease Trials
The Pink Sheet takes a closer look at recent clinical announcements showing how rare disease therapy sponsors are already increasingly reliant on natural history studies to guide drug development.